Tamoxifen Inhibits Secretion of Vascular Endothelial Growth Factor in Breast Cancer in Vivo

Cancer Research

Volumn 63, Issue 24, 2003, Pages 8742-8748

  Garvin, Stina ^a   Dabrosin, Charlotta ^a  

^a LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; MESSENGER RNA; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TAMOXIFEN; VASCULOTROPIN; VASCULOTROPIN A;

ANGIOGENESIS; ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOSYNTHESIS; BREAST CANCER; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CELL CULTURE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CULTURE MEDIUM; DRUG EFFECT; DRUG EFFICACY; DRUG INHIBITION; DRUG SCREENING; ESTROGEN THERAPY; EXTRACELLULAR SPACE; FEMALE; GENETICS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METABOLISM; MICRODIALYSIS; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SECRETION; SOLID TUMOR; TUMOR CELL LINE; VASCULARIZATION; WESTERN BLOTTING;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL LINE, TUMOR; ESTRADIOL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, NUDE; MICRODIALYSIS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ESTROGEN; RNA, MESSENGER; SECRETORY RATE; TAMOXIFEN; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 0346059598     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med., 1: 27-31, 1995.
2. Neufeld, G., Cohen, T., Gengrinovitch, S., and Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J., 13: 9-22, 1999.
3. Yoshiji, H., Gomez, D. E., Shibuya, M., and Thorgeirsson, U. P. Expression of vascular endothelial growth factor, its receptor, and other angiogenic factors in human breast cancer. Cancer Res., 56: 2013-2016, 1996.
4. Linderholm, B., Grankvist, K., Wilking, N., Johansson, M., Tavelin, B., and Henriksson, R. Correlation of vascular endothelial growth factor content with recurrences, survival, and first relapse site in primary node-positive breast carcinoma after adjuvant treatment. J. Clin. Oncol., 18: 1423-1431, 2000.
5. Linderholm, B., Tavelin, B., Grankvist, K., and Henriksson, R. Vascular endothelial growth factor is of high prognostic value in node-negative breast carcinoma. J. Clin. Oncol., 16: 3121-3128, 1998.
6. Tischer, E., Mitchell, R., Hartman, T., Silva, M., Gospodarowicz, D., Fiddes, J. C., and Abraham, J. A. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem., 266: 11947-11954, 1991.
7. Zhang, H. T., Scott, P. A., Morbidelli, L., Peak, S., Moore, J., Turley, H., Harris, A. L., Ziche, M., and Bicknell, R. The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br. J. Cancer, 83: 63-68, 2000.
8. Losordo, D. W., and Isner, J. M. Estrogen and angiogenesis: a review. Arterioscler. Thromb. Vasc. Biol., 21: 6-12, 2001.
9. Hyder, S. M., and Stancel, G. M. Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins. Mol. Endocrinol., 13: 806-811, 1999.
10. Hyder, S. M., Nawaz, Z., Chiappetta, C., and Stancel, G. M. Identification of functional estrogen response elements in the gene coding for the potent angiogenic factor vascular endothelial growth factor. Cancer Res., 60: 3183-3190, 2000.
11. Rossouw, J. E., Anderson, G. L., Prentice, R. L., LaCroix, A. Z., Kooperberg, C., Stefanick, M. L., Jackson, R. D., Beresford, S. A., Howard, B. V., Johnson, K. C., Kotchen, J. M., and Ockene, J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA, 288: 321-333, 2002.
12. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet, 348: 1189-1196, 1996.
13. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet, 350: 1047-1059, 1997.
14. Ruohola, J. K., Valve, E. M., Karkkainen, M. J., Joukov, V., Alitalo, K., and Harkonen, P. L. Vascular endothelial growth factors are differentially regulated by steroid hormones and antiestrogens in breast cancer cells. Mol. Cell. Endocrinol., 149: 29-40, 1999.
15. Bogin, L., and Degani, H. Hormonal regulation of VEGF in orthotopic MCF7 human breast cancer. Cancer Res., 62: 1948-1951, 2002.
16. Brunk, U. T., Dalen, H., Roberg, K., and Hellquist, H. B. Photo-oxidative disruption of lysosomal membranes causes apoptosis of cultured human fibroblasts. Free Radic. Biol. Med., 23: 616-626, 1997.
17. Ungerstedt, U. Microdialysis-principles and applications for studies in animals and man. J. Intern. Med., 230: 365-373, 1991.
18. Dabrosin, C., Margetts, P. J., and Gauldie, J. Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int. J. Cancer, 107: 535-540, 2003.
19. Dabrosin, C. Variability of vascular endothelial growth factor in normal human breast tissue in vivo during the menstrual cycle. J. Clin. Endocrinol. Metab., 88: 2695-2698, 2003.
20. Schor, A. M., Pendleton, N., Pazouki, S., Smither, R. L., Morris, J., Lessan, K., Heerkens, E., Chandrachud, L. M., Carmichael, G., Adi, M., Chisholm, D. M., and Stevenson, H. Assessment of vascularity in histological sections: effects of methodology and value as an index of angiogenesis in breast tumours. Histochem. J., 30: 849-856, 1998.
21. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275, 1951.
22. Kimura, H., Weisz, A., Ogura, T., Hitomi, Y., Kurashima, Y., Hashimoto, K., D'Acquisto, F., Makuuchi, M., and Esumi, H. Identification of hypoxia-inducible factor 1 ancillary sequence and its function in vascular endothelial growth factor gene induction by hypoxia and nitric oxide. J. Biol. Chem., 276: 2292-2298, 2001.
23. Houck, K. A., Leung, D. W., Rowland, A. M., Winer, J., and Ferrara, N. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms. J. Biol. Chem., 267: 26031-26037, 1992.
24. Ferrara, N., and Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev., 18: 4-25, 1997.
25. Lee, A. H., Dublin, E. A., Bobrow, L. G., and Poulsom, R. Invasive lobular and invasive ductal carcinoma of the breast show distinct patterns of vascular endothelial growth factor expression and angiogenesis. J. Pathol., 185: 394-401, 1998.
26. Toi, M., Kondo, S., Suzuki, H., Yamamoto, Y., Inada, K., Imazawa, T., Taniguchi, T., and Tominaga, T. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer, 77: 1101-1106, 1996.
27. Relf, M., LeJeune, S., Scott, P. A., Fox, S., Smith, K., Leek, R., Moghaddam, A., Whitehouse, R., Bicknell, R., and Harris, A. L. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor â-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis. Cancer Res., 57: 963-969, 1997.
28. Banks, R. E., Forbes, M. A., Kinsey, S. E., Stanley, A., Ingham, E., Walters, C., and Selby, P. J. Release of the angiogenic cytokine vascular endothelial growth factor (VEGF) from platelets: significance for VEGF measurements and cancer biology. Br. J. Cancer, 77: 956-964, 1998.
29. Adams, J., Carder, P. J., Downey, S., Forbes, M. A., MacLennan, K., Allgar, V., Kaufman, S., Hallam, S., Bicknell, R., Walker, J. J., Cairnduff, F., Selby, P. J., Perren, T. J., Lansdown, M., and Banks, R. E. Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen. Cancer Res., 60: 2898-2905, 2000.
30. Rifkin, D. B., Moscatelli, D., Bizik, J., Quarto, N., Blei, F., Dennis, P., Flaumenhaft, R., and Mignatti, P. Growth factor control of extracellular proteolysis. Cell Differ. Dev., 32: 313-318, 1990.
31. Kurizaki, T., Toi, M., and Tominaga, T. Relationship between matrix metalloproteinase expression and tumor angiogenesis in human breast carcinoma. Oncol. Rep., 5: 673-677, 1998.
32. Sounni, N. E., Devy, L., Hajitou, A., Frankenne, F., Munaut, C., Gilles, C., Deroanne, C., Thompson, E. W., Foidart, J. M., and Noel, A. MTI-MMP expression promotes tumor growth and angiogenesis through an up-regulation of vascular endothelial growth factor expression. FASEB J., 16: 555-564, 2002.
33. Dabrosin, C. Technical aspects of microdialysis of human breast. Scand. J. Clin. Lab. Investig., 61: 269-272, 2001.
34. Dabrosin, C., Ollinger, K., Ungerstedt, U., and Hammar, M. Variability of glutathione levels in normal breast tissue and subcutaneous fat during the menstrual cycle: an in vivo study with microdialysis technique. J. Clin. Endocrinol. Metab., 82: 1382-1384, 1997.,
35. Dabrosin, C. Increase of free insulin-like growth factor-1 in normal human breast in vivo late in the menstrual cycle. Breast Cancer Res. Treat., 80: 193-198, 2003.
36. Harris, A. L. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer, 2: 38-47, 2002.